SAM #NOI-OLAO-CC-26-003467

Five-Year Sole Source Service Contract for Cytek Aurora 3 Laser Flow Cytometers at NIH and NCI

This opportunity involves a planned five-year, sole source service contract for Cytek Aurora 3 Laser flow cytometers at NIH and NCI facilities in Maryland. - The contract covers maintenance, preventive services, repairs, software updates, and technical support for Cytek Aurora 3 Laser flow cytometers (Serial Number: R1623/FH101). - Includes one base year and four option years (total five years, July 2026 – July 2031). - Services include annual preventive maintenance, emergency on-site service (24-48 hour response), unlimited service visits, and telephone support. - Ensures compliance with FDA 21 CFR 211.67 for clinical lab operations and supports high-throughput clinical research and cell therapy product development. - Cytek Biosciences is the only OEM identified and is considered the sole source due to proprietary technology and regulatory requirements. - Estimated contract value is approximately $100,000–$120,000 for the five-year period. - Place of performance includes NIH Clinical Center in Bethesda, MD, and NCI Frederick in Frederick, MD. - No competing products or alternative OEMs are explicitly listed, but other flow cytometer manufacturers may exist. - No new equipment is being procured; this is strictly for service and maintenance.

Description

This is a Notice of Intent, not a request for proposal.  The National Institute of Health intends to negotiate on an other than full and open competition basis with the following vendor: Cytek Biosciences.

Acquisition Description:

This is a five-year (one base year plus 4 option years) of service contract for Cytek Aurora 3 laser flow cytometers (S/N: R1623/FH101). These instruments are used to process patient samples including both licensed blood products and cellular therapy products, and to identify cell population from blood and cell products for clinical research and cell therapeutic product development. It can also provide guidance in test of our gene modification efficiencies, and QC our cell selection methods.

The statutory authority for this sole source requirement is 41 U.S.C. 253(c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL.  All responsible sources that could provide the required may submit a capability statement that will be considered by email (subject line to reference NOI-OLAO-CC-26-003467) by 12:00 PM eastern standard time on 04/23/2026 to: valerie.gregorio@nih.gov.

All responses received by the closing date of this synopsis will be considered by the Government.  A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

View original listing